title: Atopic dermatitis - from new pathophysiologic insights to individualized therapy.
abstract: Recently, important novel insights into the complex pathophysiology of atopic dermatitis (AD) have been gained. However, in most cases the therapy of AD is limited to base line therapy with emollients combined with symptomatic, rather general immunosuppressive treatment approaches of the flare-ups. Latest research findings together with experiences from daily clinical practice, which support the concept that a combination of general disease features together with specific trigger factors in the individual patients drive the disease, might be helpful for a subclassification of patients with AD based on the most relevant pathophysiologic modifications. Subclassification of patients with AD seems indispensable to introduce rationale-based, individualized treatment approaches of AD, which target specific modified pathways. In this review, we provide an overview about a selection of pathophysiologic pathways, which hold promise to represent targets of such therapeutic approaches in the near future.
authors.affiliation: Department of Dermatology and Allergy, University of Bonn, Bonn, Germany. Natalija.Novak@ukb.uni-bonn.de
authors.forename: Natalija
authors.initials: N
authors.lastname: Novak
authors.forename: D
authors.initials: D
authors.lastname: Simon
mesh_terms: D023181:Antimicrobial Cationic Peptides / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy*; D000091344:Filaggrin Proteins; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D007381:Intermediate Filament Proteins / Q000235:genetics; D009154:Mutation
chemical_list: D023181:Antimicrobial Cationic Peptides; D000091344:Filaggrin Proteins; D007166:Immunosuppressive Agents; D007381:Intermediate Filament Proteins